Treatment of primary HIV-1 infection with nonnucleoside reverse transcriptase inhibitor-based therapy is effective and well tolerated

HIV Medicine

Volumn 5, Issue 1, 2004, Pages 26-29

  Portsmouth, Simon ^a   Imami, N ^b   Pires, A ^b   Stebbing, J ^b   Hand, J ^a   Nelson, M ^a   Gotch, F ^b   Gazzard, B G ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

HIV; Nonnucleoside reverse transcriptase inhibitor; Primary infection

Indexed keywords

ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; CD16 ANTIGEN; CD38 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; EFAVIRENZ; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; BLOOD TOXICITY; CLINICAL ARTICLE; CONTROLLED STUDY; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOASSAY; LIPODYSTROPHY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE FUNCTION; MALE; MENTAL DISEASE; NAUSEA; PRIMARY INFECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SLEEP DISORDER; VIRUS LOAD; VIVID DREAM;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-CD8 RATIO; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; FLOW CYTOMETRY; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; OXAZINES; REVERSE TRANSCRIPTASE INHIBITORS; VIRAL LOAD; ZIDOVUDINE;

EID: 1242296299     PISSN: 14642662     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2004.00181.x     Document Type: Article

References (11)

1. Mellors JW, Kingsley LA, Rinaldo CR Jr. et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995; 122: 573-579.
2. Palella FJ Jr., Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection HIV. Outpatient Study Investigators. N Engl J Med 1998; 338: 853-860.
3. Markowitz M, Vesanen M, Tenner-Racz K et al. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses. J Infect Dis 1999; 179: 527-537.
4. Negredo E, Ciuz L, Paredes R et al. Virological, immunological and clinical impact of switching from protease inhibitors to nevirapine or efavirenz in patients with human immunodeficiency virus infection and long lasting suppression. Clin Inf Dis 2002; 34: 504-510.
5. Gazzard B, Moyle G. Revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. BHIVA Guidelines Writing Committee. Lancet 1998; 352: 314-316.
6. British HIV Association (BHIVA). Guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2001; 2: 276-313.
7. Altfeld M, Walker BD. Less is more? STI in acute and chronic HIV-1 infection. Nature Med 2001; 7: 881-884.
8. Oxenius A, Price DA, Easterbrook PJ et al. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8 + and CD4 + T lymphocytes. Proc Natl Acad Sci USA 2000; 97: 3382-3387.
9. Kovacs A, Wasserman SS, Burns D et al. Determinants of HIV-1 shedding in the genital tract of women. Lancet 2001; 358: 1593-1601.
10. Giorgi JV, Lyles RH Matud JL et al. Predictive value of immunologic and virologic markets after long or short duration of HIV-1 infection. J AIDS 2002; 29: 346-355.
11. Al-Harthi L, Siegel J, Spritzler J et al. Maximum suppression of HIV replication leads to the restoration of HIV specific responses in early HIV disease. AIDS 2000; 14: 761-770.